Drug adverse events in patients with metastatic bone tumors

Objective To explore clinical features of drug adverse events(DAEs) in patients with metastatic bone tumor treated with antitumor drug and to provide scientific basis for rational use of antitumor drug and reduction of DAEs.Methods Medical records 11238 metastatic bone tumor inpatients were retrospectively collected from 4 hospitals in Shenyang city between January 2004 through January 2014.Incidents of DAEs among the patients registered were analyzed by demographic characteristics, type and pharmaceutical dosage form, and organ and system distribution of the antitumor drugs used by the patients.Results A total of 30122 DAEs were identified among 8242 metastatic bone tumor inpatients during the period; of the inpatients with DAEs, 61.64% were male and 38.36% were female; 47.00% were at the ages of 45 to 64 years and 74.99% were aged over 45 years.Of the DAEs identified, 39.91% were induced by other antitumor drugs and supplementary therapy drugs and 95.43% were related to the injections of the antitumor drugs; digestive system was the mostly involved by the DAEs, accounting for 22.63% of all DAEs identified.Conclusion Researches on pharmacoepidemiological features of DAEs among inpatients with metastatic bone tumor under chemotherapy could promote rational drug antitumor drug use and reduce the incidence of DAEs.